Catalent (CTLT) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Catalent, Inc. Reports First Quarter Fiscal Year 2017 Results
November 7, 2016 4:15 PM ESTQ1'17 revenue $442.2 million increased 5% as-reported, or 7% in constant currency from the prior year period. Acquired Pharmatek Laboratories, a West Coast, U.S.-based specialist in drug development and clinical manufacturing; adds extensive formulation and development capabilities. Triphase Accelerator has obtained worldwide rights to an oncology treatment developed using Catalent's proprietary SMARTag technology. Reached an agreement with Moderna Therapeutics to support near-term Good Manufacturing Practice (GMP) efforts for Phase 1/2 clinical studies for its personalized cancer vaccines.... More
